WILMINGTON, Del., March 11, 2024 (GLOBE NEWSWIRE) — The U.S. Patent and Trademark Office has issued a patent, US11920140, for the use of CRISPR technologies to edit organellar genomes to NAPIGEN, Inc., a biotechnology company that specializes in mitochondrial and chloroplast genome engineering.
